1910 Genetics Receives Investment from Accenture Ventures
Summary
1910 Genetics, a Boston, MA-based biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform empowered by laboratory automation, received an investment from Accenture Ventures. Founded by CEO Jen Nwankwo, 1910 Genetics is a small and large molecule drug discovery company providing multimodal AI platform empowered by laboratory automation. It integrates AI that leverages federated learning alongside three proprietary data streams to deliver novel drug candidates and software solutions to biopharma and tech partners, and advance its internal pipeline for neurological, autoimmune diseases, and cancer. In conjunction with this announcement, Dr. Petra Jantzer and Tom Lounibos will join the Business Advisory Board of 1910, and Dr. Kailash Swarna, a managing director in Life Sciences at Accenture, and Dr. Cecil Lynch, Biomedical Informatics lead at Accenture, will join the Technology Advisory Board of 1910. As part of this investment, Accenture and 1910 will collaborate to combine tailored solutions and scalable infrastructure to help clients in the biopharma industry accelerate drug target identification, reduce costs, and deliver better, more affordable therapies to patients.